Chantal reports record first quarter sales and earnings of $.24 per share.LOS ANGELES--(BUSINESS WIRE)--November 15, 1995--Chantal Pharmaceutical Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CHTL) today reported record results for the first quarter of fiscal 1996, ending Sept. 30. For the quarter the company achieved net income of $4,198,615 or $.24 per share on revenue from product sales of $11,285,527. For the quarter ending Sept. 30, 1994, the company reported product revenue of $269,817 with a loss of $483,890 or $.04 per share. Chantal Burnison, chairman and chief executive officer of the company, noted that this is the third record consecutive quarter of increasing earnings for the company, resulting from the aggressive marketing efforts for the Chantal Ethocyn Skin Care line of products by the company and its distributor, Stanson Medical Marketing. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Burnison, sales of the Ethocyn-based Chantal Skin Care Products continue to be strong, expecially through the chain and independent drug stores. She also noted that sales to dermatologists and plastics surgeons were especially noteworthy. "We are pleased with the response that the products receive at the retail level. The company is working intensively with Stanson to meet retail store demands where sell-through of Chantal Skin Care Products continues to exceed expectations." Chantal Pharmaceutical Corporation has executive offices, telemarketing telemarketing, the practice of selling goods or services to customers by means of the telephone or of surveying consumer preferences in telephone conversations. and warehouse facilities in Los Angeles Los Angeles (lôs ăn`jələs, lŏs, ăn`jəlēz'), city (1990 pop. 3,485,398), seat of Los Angeles co., S Calif.; inc. 1850. , with a laboratory in Kaiserslautern, Germany. In addition to marketing the Chantal Ethocyn Skin Care Line, the company is engaged in the research and development of topical and systemic pharmaceutical and therapeutic compounds for the treatment of androgen androgen (ăn`drəjən): see testosterone. androgen Any of a group of hormones that mainly influence the development of the male reproductive system. mediated disorders such as acne, hirsutism Hirsutism Definition Excessive growth of facial or body hair in women is called hirsutism. Description Hirsutism is not a disease. The condition usually develops during puberty and becomes more pronounced as the years go by. , male pattern baldness male pattern baldness n. A progressive, diffuse loss of scalp hair in men that begins in the twenties or early thirties, depends on the presence of the androgenic hormone testosterone, and is caused by a combination of genetic and hormonal factors. , benign prostate hypertrophy hypertrophy (hīpûr`trəfē), enlargement of a tissue or organ of the body resulting from an increase in the size of its cells. Such growth accompanies an increase in the functioning of the tissue. and the treatment of certain cancers. -0-
Chantal Pharmaceutical Corporation Chart
Quarter Ending Sept. 30,
1996 1995
Product revenue $ 11,285,527 $ 269,817 Net income (loss) $ 4,198,615 $ (483,890) Net income (loss) per share $ .24 $ (.04) Weighted average shares outstanding 17,817,183 11,333,850 CONTACT: Martin E. Janis & Company, Inc. Bev Jedynak 312/943-1100 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion